Methods of induction of labor and women's experience: a population-based cohort study with mediation analyses.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
14 Sep 2021
Historique:
received: 15 12 2020
accepted: 26 07 2021
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 7 1 2022
Statut: epublish

Résumé

Negative childbirth experience may affect mother wellbeing and health. However, it is rarely evaluated in studies comparing methods of induction of labor (IoL). To compare women's experience of IoL according to the method, considering the mediating role of interventions and complications of delivery. We used data from the MEDIP prospective population-based cohort, including all women with IoL during one month in seven French perinatal networks. The experience of IoL, assessed at 2 months postpartum, was first compared between cervical ripening and oxytocin, and secondarily between different cervical ripening methods. Mediation analyses were used to measure the direct and indirect effects of cervical ripening on maternal experience, through delivery with interventions or complications. The response rate was 47.8% (n = 1453/3042). Compared with oxytocin (n = 541), cervical ripening (n = 910) was associated less often with feelings that labor went 'as expected' (adjusted risk ratio for the direct effect 0.78, 95%CI [0.70-0.88]), length of labor was 'acceptable' (0.76[0.71-0.82]), 'vaginal discomfort' was absent (0.77[0.69-0.85]) and with lower global satisfaction (0.90[0.84-0.96]). Interventions and complications mediated between 6 and 35% of the total effect of cervical ripening on maternal experience. Compared to the dinoprostone insert, maternal experience was not significantly different with the other prostaglandins. The balloon catheter was associated with less pain. Cervical ripening was associated with a less positive experience of childbirth, whatever the method, only partly explained by interventions and complications of delivery. Counselling and support of women requiring cervical ripening might be enhanced to improve the experience of IoL.

Sections du résumé

BACKGROUND BACKGROUND
Negative childbirth experience may affect mother wellbeing and health. However, it is rarely evaluated in studies comparing methods of induction of labor (IoL).
AIM OBJECTIVE
To compare women's experience of IoL according to the method, considering the mediating role of interventions and complications of delivery.
METHODS METHODS
We used data from the MEDIP prospective population-based cohort, including all women with IoL during one month in seven French perinatal networks. The experience of IoL, assessed at 2 months postpartum, was first compared between cervical ripening and oxytocin, and secondarily between different cervical ripening methods. Mediation analyses were used to measure the direct and indirect effects of cervical ripening on maternal experience, through delivery with interventions or complications.
FINDINGS RESULTS
The response rate was 47.8% (n = 1453/3042). Compared with oxytocin (n = 541), cervical ripening (n = 910) was associated less often with feelings that labor went 'as expected' (adjusted risk ratio for the direct effect 0.78, 95%CI [0.70-0.88]), length of labor was 'acceptable' (0.76[0.71-0.82]), 'vaginal discomfort' was absent (0.77[0.69-0.85]) and with lower global satisfaction (0.90[0.84-0.96]). Interventions and complications mediated between 6 and 35% of the total effect of cervical ripening on maternal experience. Compared to the dinoprostone insert, maternal experience was not significantly different with the other prostaglandins. The balloon catheter was associated with less pain.
DISCUSSION CONCLUSIONS
Cervical ripening was associated with a less positive experience of childbirth, whatever the method, only partly explained by interventions and complications of delivery.
CONCLUSION CONCLUSIONS
Counselling and support of women requiring cervical ripening might be enhanced to improve the experience of IoL.

Identifiants

pubmed: 34521377
doi: 10.1186/s12884-021-04076-x
pii: 10.1186/s12884-021-04076-x
pmc: PMC8442398
doi:

Substances chimiques

Oxytocics 0
Oxytocin 50-56-6

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

621

Investigateurs

Catherine Crenn-Hebert (C)
Adrien Gaudineau (A)
Frédérique Perrotte (F)
Pierre Raynal (P)
Elodie Clouqueur (E)
Gaël Beucher (G)
Catherine Deneux-Tharaux (C)
Pierre-Yves Ancel (PY)

Informations de copyright

© 2021. The Author(s).

Références

Am J Obstet Gynecol. 2017 Aug;217(2):167-175
pubmed: 28427805
BJOG. 2009 Oct;116(11):1443-52
pubmed: 19656148
BJOG. 2002 Mar;109(3):254-60
pubmed: 11950179
N Engl J Med. 2018 Aug 09;379(6):513-523
pubmed: 30089070
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:189-195
pubmed: 28056435
J Gynecol Obstet Hum Reprod. 2018 Feb;47(2):57-62
pubmed: 29196154
Am J Obstet Gynecol. 2019 Oct;221(4):304-310
pubmed: 30817905
BMC Pregnancy Childbirth. 2011 Oct 27;11:84
pubmed: 22032440
Birth. 2018 Mar;45(1):64-70
pubmed: 28921607
Am J Obstet Gynecol. 2020 Apr;222(4):320-329
pubmed: 31398311
Midwifery. 2017 Aug;51:33-39
pubmed: 28528179
Am J Epidemiol. 2015 Mar 1;181(5):349-56
pubmed: 25693776
BMJ. 2015 Feb 05;350:h217
pubmed: 25656228
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
Obstet Gynecol. 2015 Dec;126(6):1258-1264
pubmed: 26551184
BJOG. 2019 Jul;126(8):983
pubmed: 30893492
PLoS One. 2017 Jan 3;12(1):e0169132
pubmed: 28046019
Acta Obstet Gynecol Scand. 2013 Mar;92(3):318-24
pubmed: 23278249
BMC Pregnancy Childbirth. 2013 Jan 29;13:25
pubmed: 23356673
Paediatr Perinat Epidemiol. 2019 Sep;33(5):313-322
pubmed: 31342567
Eur J Obstet Gynecol Reprod Biol. 2005 Nov 1;123(1):56-61
pubmed: 15905017
Gynecol Obstet Fertil Senol. 2019 Jul - Aug;47(7-8):555-561
pubmed: 31153953
Stat Med. 2013 Nov 20;32(26):4567-80
pubmed: 23744517
Obstet Gynecol. 2009 Aug;114(2 Pt 1):386-397
pubmed: 19623003
J Gynecol Obstet Hum Reprod. 2017 Dec;46(10):701-713
pubmed: 29031048
BMC Pregnancy Childbirth. 2016 May 18;16(1):114
pubmed: 27193995
BJOG. 2016 Aug;123(9):1501-8
pubmed: 27173131
BJOG. 2016 Feb;123(3):346-54
pubmed: 26538408
BJOG. 2018 Dec;125(13):1673-1680
pubmed: 29981523
Arch Womens Ment Health. 2019 Oct;22(5):613-620
pubmed: 30353272
Acta Obstet Gynecol Scand. 2013 Oct;92(10):1159-67
pubmed: 23808325
Midwifery. 2016 Aug;39:112-23
pubmed: 27321728
BMJ Open. 2013 Jan 03;3(1):
pubmed: 23293244
Midwifery. 2019 Feb;69:17-28
pubmed: 30390463
Midwifery. 2011 Dec;27(6):e231-7
pubmed: 21145632
Acta Obstet Gynecol Scand. 2006;85(5):551-60
pubmed: 16752233
Acta Obstet Gynecol Scand. 2021 Jul;100(7):1313-1321
pubmed: 33792924
Midwifery. 2018 Dec;67:46-56
pubmed: 30232052
BJOG. 2002 Jun;109(6):618-23
pubmed: 12118637
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003246
pubmed: 19821304
Midwifery. 2016 Dec;43:21-28
pubmed: 27825057

Auteurs

Pauline Blanc-Petitjean (P)

Université de Paris, CRESS, INSERM, INRA, F-75004, Paris, France. pauline.blanc-petitjean@inserm.fr.
Department of Obstetrics and Gynecology, AP-HP, Louis Mourier Hospital, DHU Risks in pregnancy, Université de Paris, F-92700, Colombes, France. pauline.blanc-petitjean@inserm.fr.

Corinne Dupont (C)

Réseau périnatal Aurore - Hôpital de la Croix Rousse, Université Lyon 1, HESPER EA 7425 Health Services and Performance Research, F-69008, Lyon, France.

Bruno Carbonne (B)

Department of Obstetrics and Gynecology, Princess Grace Hospital, Monaco, France.

Marina Salomé (M)

AP-HP, URC-CIC Paris Descartes Necker/Cochin, F-75014, Paris, France.

François Goffinet (F)

Université de Paris, CRESS, INSERM, INRA, F-75004, Paris, France.
AP-HP, Cochin Hospital, Port Royal Maternity Unit, DHU Risks in Pregnancy, Université de Paris, F-75014, Paris, France.

Camille Le Ray (CL)

Université de Paris, CRESS, INSERM, INRA, F-75004, Paris, France.
AP-HP, Cochin Hospital, Port Royal Maternity Unit, DHU Risks in Pregnancy, Université de Paris, F-75014, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH